Anondita Medicare Limited reported a robust financial performance for the fiscal year ended March 31, 2026, with a 108% year-on-year surge in profit after tax (PAT) to ₹3,429.65 lakh. Revenue from operations grew 78% to ₹13,741.57 lakh, while EBITDA increased 100% to ₹5,150.85 lakh, driven by operational efficiency and market penetration. The strong momentum continued in the second half, with H2 FY26 PAT rising 103% to ₹2,127.86 lakh and revenue increasing 83% to ₹8,331.87 lakh.

The board approved the audited standalone and consolidated financial results on May 22, 2026. The company submitted the Integrated Filing (Financial) to the National Stock Exchange of India under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors provided an unmodified opinion on the consolidated results.

Financial Highlights

The following table summarizes the key financial figures for FY26 compared to the prior year:

For the six months ended March 31, 2026, the EBITDA margin expanded to 38.29% from 35.02% in H2 FY25, an increase of 327 basis points. The PAT margin for the period improved to 25.54% from 22.98%.

Operational Performance

Total income for FY26 stood at ₹13,825.81 lakh, with total expenses amounting to ₹9,136.85 lakh. The basic and diluted earnings per share (EPS) for the year were recorded at ₹21.3. Total shareholders' funds as of March 31, 2026, were reported at ₹12,923.58 lakh.

Mr. Anupam Ghosh, Managing Director, attributed the growth to capacity enhancement and expanding international presence. The company operates its flagship brand "COBRA" and is focused on automation-led capacity enhancement and innovative patented female condom products.

anondita medicare has secured a purchase order worth ₹7,18,36,178.31 from the Central Medical Services Society (CMSS), Ministry of Health and Family Welfare. The order, dated April 28, 2026, is for the supply of condoms (FS-NACO) and was disclosed to the National Stock Exchange of India Limited on May 25, 2026. The company confirmed that the disclosure was made after obtaining necessary clarifications from CMSS regarding the final accepted quantity and the applicability of the Rate Contract.

Order Details

The purchase order (PO No: 10282600131/PDI/Domestic Fund-DF) stipulates a delivery schedule divided into two tranches. The first tranche requires 50% of the total delivery to be completed within 90 days from the date of the purchase order. The remaining 50% must be delivered within 91 to 180 days from the purchase order date.

Financial and Contractual Terms

The total value of the order is ₹7,18,36,178.31. The contract requires the company to deposit a performance security equivalent to 3% of the total order value via NEFT, RTGS, Demand Draft, Banker's Cheque, Fixed Deposit Receipt, or Bank Guarantee. This security must be submitted within 15 days of receiving the order letter, or the amount will be deducted from payments due.

Payment terms are structured based on the type of supplies. For items requiring sterility tests, payments will be made within 75 days of supply. For other items, the payment timeline is 60 days. Part payments will only be considered after 50% of the ordered items in an individual tranche have been supplied, provided standard quality testing reports are received from CMSS laboratories.

The company confirmed that the order has been awarded by a domestic entity and that there is no interest from the promoter, promoter group, or group companies in the entity awarding the order. The transaction does not fall under related party transactions.